Aytu Bioscience Stock Beta
AYTU Stock | USD 1.65 0.05 2.94% |
Aytu BioScience fundamentals help investors to digest information that contributes to Aytu BioScience's financial success or failures. It also enables traders to predict the movement of Aytu Stock. The fundamental analysis module provides a way to measure Aytu BioScience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aytu BioScience stock.
Aytu | Beta |
Aytu BioScience Company Beta Analysis
Aytu BioScience's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Aytu BioScience Beta | -1.4 |
Most of Aytu BioScience's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aytu BioScience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aytu Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Aytu BioScience is extremely important. It helps to project a fair market value of Aytu Stock properly, considering its historical fundamentals such as Beta. Since Aytu BioScience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aytu BioScience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aytu BioScience's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Competition |
In accordance with the recently published financial statements, Aytu BioScience has a Beta of -1.402. This is 263.02% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The beta for all United States stocks is notably higher than that of the company.
Aytu Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aytu BioScience's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aytu BioScience could also be used in its relative valuation, which is a method of valuing Aytu BioScience by comparing valuation metrics of similar companies.Aytu BioScience is currently under evaluation in beta category among its peers.
Aytu BioScience Institutional Holders
Institutional Holdings refers to the ownership stake in Aytu BioScience that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aytu BioScience's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aytu BioScience's value.Shares | Advisor Group Holdings, Inc. | 2024-09-30 | 300 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 290 | Ubs Group Ag | 2024-09-30 | 260 | Wells Fargo & Co | 2024-09-30 | 124 | Bank Of America Corp | 2024-09-30 | 98.0 | Atlantic Trust Group, Llc | 2024-09-30 | 83.0 | Group One Trading, Lp | 2024-09-30 | 37.0 | Goss Wealth Management Llc | 2024-09-30 | 21.0 | U.s. Bancorp | 2024-06-30 | 9.0 | Nantahala Capital Management, Llc | 2024-09-30 | 1.1 M | Stonepine Capital Management Llc | 2024-09-30 | 501 K |
As returns on the market increase, returns on owning Aytu BioScience are expected to decrease by larger amounts. On the other hand, during market turmoil, Aytu BioScience is expected to outperform it.
Aytu Fundamentals
Return On Equity | -0.47 | ||||
Return On Asset | -0.0106 | ||||
Profit Margin | (0.20) % | ||||
Operating Margin | (0.04) % | ||||
Current Valuation | 6.6 M | ||||
Shares Outstanding | 6.15 M | ||||
Shares Owned By Insiders | 2.43 % | ||||
Shares Owned By Institutions | 34.04 % | ||||
Number Of Shares Shorted | 120.8 K | ||||
Price To Earning | (0.77) X | ||||
Price To Book | 0.34 X | ||||
Price To Sales | 0.13 X | ||||
Revenue | 81 M | ||||
Gross Profit | 66.63 M | ||||
EBITDA | (1.01 M) | ||||
Net Income | (15.84 M) | ||||
Cash And Equivalents | 23.81 M | ||||
Cash Per Share | 0.38 X | ||||
Total Debt | 15.13 M | ||||
Debt To Equity | 0.47 % | ||||
Current Ratio | 1.02 X | ||||
Book Value Per Share | 4.64 X | ||||
Cash Flow From Operations | (1.39 M) | ||||
Short Ratio | 10.45 X | ||||
Earnings Per Share | (1.70) X | ||||
Target Price | 8.0 | ||||
Number Of Employees | 102 | ||||
Beta | -1.4 | ||||
Market Capitalization | 10.45 M | ||||
Total Asset | 118.09 M | ||||
Retained Earnings | (319.97 M) | ||||
Working Capital | (337 K) | ||||
Current Asset | 6.36 M | ||||
Current Liabilities | 8.73 M | ||||
Net Asset | 118.09 M |
About Aytu BioScience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aytu BioScience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aytu BioScience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aytu BioScience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.